Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on May 09, 2021 8:54am

212 Views

Post# 33161427

Re: WHO

Good article Maverick ...that's how I was kind of thinking Claritas would possibly operate ....other countries could access to our R107 to manufacture or produce and we get kick backs on all aspects of growth ... it greatly takes value out of patents on specific ownership ...but this scenario is unique in a desperation to save human lives gloabally... to want to try to keep individual control due to financial gain is selfish at this time ...this virus can keep mutating and could potentially wipe out countries...this imo .glta

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success